(1) Poschke, I., Mao, Y., Adamson, L., Salazar-Onfray, F., Masucci, G., Kiessling, R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol. Immunother. 61, 827-838 (2012).
(2) Tjomsland, V., Spångeus, A., Sandström, P., Borch, K., Messmer, D., Larsson, M. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumour. PLoS One. 5, e13441 (2010).
(3) Choi, K. D., Vodyanik, M. A., Slukvin, I. I. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. J. Clin. Investg. 119, 2818–2829 (2009).
(4) Senju, S. et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells. 27, 1021–1031 (2009).
(5) Senju, S. et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther. 18, 874–883 (2011).
(6) Silk, K. M. et al. Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. Gene Ther. 19, 1035–1040 (2012).
(7) Yanagimachi, M. D. et al. Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS One. 8, e59243 (2013).
(8) Iwamoto, H. et al. Antitumor immune response of dendritic cells (DCs) expressing tumour-associated antigens derived from induced pluripotent stem cells: In comparison to bone marrow-derived DCs. Int. J. Cancer. 134, 332–341 (2014)
(9) Kitadani, J. et al. Cancer vaccine therapy using carcinoembryonic antigen expressing dendritic cells generated from induced pluripotent stem cells. Sci. Rep. 8, 4569 (2018).
(10) Yarchoan, M., Johnson, B. A. 3rd., Lutz, E. R., Laheru, D.A., Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer. 17, 209–222 (2017).
(11) Rosenberg, S. A., Yang, J. C., Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10, 909–915 (2004).
(12) Boczkowski, D., Nair, S. K., Nam, J. H., Lyerly, H. K., Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028–1034 (2000).
(13) Vik-Mo, EO. et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 62, 1499–1509 (2013).
(14) Ban, H. et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA. 108, 14234–14239 (2011).
(15) Nishishita, N., Takenaka, C., Fusaki, N., Kawamata, S. Generation of human induced pluripotent stem cells from cord blood cells. J. Stem Cells. 6, 101–108 (2011).
(16) Kondo, J. et al. High-throughput screening in colorectal cancer tissue-originated spheroids. Cancer Sci. 110, 345–355 (2019).
(17) Schaft, N. et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting deﬁned RNAs after rather than before maturation. J. Immunol. 174, 3087–3097 (2005).
(18) The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487, 330–337 (2012).
(19) Liccardo, R., Rosa, M. D., Rossi, G. B., Carlomagno, N., Izzo, P., Duraturo, F. Incomplete Segregation of MSH6 Frameshift Variants with Phenotype of Lynch Syndrome. Int. J. Mol. Sci. 18, 999 (2017).
(20) Ren, L. et al. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. Oncoimmunology. 8, e1568813 (2019).
(21) Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 348, 803–808 (2015).
(22) Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221(2017).
(23) Matsuda, T. et al. Induction of Neoantigen-Speciﬁc Cytotoxic T Cells and Construction of T-cell Receptor Engineered T Cells for Ovarian Cancer. Clin. Cancer Res. 24, 5357–5367 (2018).
(24) Bonehill, A. et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 172, 6649–6657 (2004).
(25) Kondo, J. et al. Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci USA. 108, 6235–6240 (2011).
(26) Wetering, M. V. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 161, 933–945 (2015).
(27) Li, Y., Bleakley, M., Yee, C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175, 2261–2269 (2005).
(28) Alves, N. L., Arosa, F. A., Lier, R. A. W. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J. Immunol. 175, 755–762 (2005).
(29) Wölfl, M. & Greenberg, P. D. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat. Protoc. 9, 950–966 (2014).
(30) Ojima, T. et al. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Int. J. Oncol. 32, 459–466 (2008).
(31) Miyazawa, M. et al. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Cancer Lett. 305, 32–39 (2011).
(32) Ren, L. et al. Similarity and difference in tumour-infiltrating lymphocytes in original tumour tissues and those of in vitro expanded populations in head and neck cancer. Oncotarget. 9, 3805–3814 (2018).
(33) Li, H. & Durbin, R. Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 25, 1754–1760 (2009).
(34) Kato, T. et al. Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget. 9, 11009–11019 (2018).
(35) Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 478, 64–69 (2011).
(36) Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., Kohlbacher, O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 30, 3310–3316 (2014).